| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |